Discovering the Shared and Everlasting
Future of Humans and Animals

ZENOAQ aims to create a shared and everlasting future for humans and animals. Amidst efforts to improve drug development, veterinary therapy and biotechnology, ZENOAQ strives to enhance the value of animals. The core activities in ZENOAQ are deeply connected with our customers, which in turn, affects their animals in many different ways. These connections form a network that is not just limited to Japan, but is something that will also reach across international borders, creating mutual benefit for both humans and animals in the future.

Animals in Japan.

What’s New



ZENOAQ expresses its thoughts and approach during the 3rd AHIA

November 09, 2018

ZENOAQ actively participated in the 3rd annual Animal Health Innovation Asia forum held in Hong Kong and was also a panelist in the panel discussion entitled "Biotech in Japan" hosted by Mr. Joseph Harvey from Animal Pharm far left in the photo. Other panelists were Dr. Mark Micallef (ZENOAQ) from left, Dr. Yuki Ujimasa, President of AHRMS, Inc. and Prof. Takuya Mizuno from Yamaguchi University. During the discussion, ZENOAQ shared its thoughts and approach on the subject of innovation in biotech in Japan. ZENOAQ sincerely thanks all participants in particular those who asked questions, livening up the panel discussion. The discussion showed that there is great interest in the Animal Health Industry in Japan. The next Animal Health Innovation Asia forum will be held in Tokyo, Japan in November 2019 and we hope to see you there.



New York Office Set up

October 01, 2018

Zenoaq is pleased to announce the establishment of its New York branch as of October 1st, 2018. New York office is the 2nd overseas' office for Zenoaq, following the establishment of our Beijing office in 2005.

This is consistent with our intention to expand our presence internationally. In recent years, Zenoaq put biotechnology at the center of its drug discovery development, resulting in our innovative product and the world's first therapeutic product for canine atopic dermatitis applying genetic recombinant technology, "Allermmune® HDM", as well as other pipelines especially in oncology and dermatology. Allermmune® HDM is already commercially available in Japan and South Korea. We look forward to delivering our novel therapeutic solutions to patients around the world in the near future.

With its strategic portfolio, Zenoaq will strive to promote the benefits that animals bring to human beings around the world.

■■Outline of New York office■■
 Name: ZENOAQ New York Branch
 Date of Establishment: October 1, 2018
 Mailing Address: 153 E 110th street #825, New York, NY 10029, USA


Join ZENOAQ at the 30th WBC in Sapporo

August 10, 2018

ZENOAQ will participate as an exhibitor at the 30th World Buiatrics Congress in Sapporo, Japan from August 28th to September 1st, 2018. Please feel free to drop by ZENOAQ's exhibition booth at the center of the exhibition hall. We are looking forward to meeting you there.


■The 30th WBC in Sapporo


Thank You for Joining Zenoaq at the Animal Health Innovation LATAM 2018 (May 29-30)

June 22, 2018

Our sincerest gratitude to all those who spent time with us during the event, where we extended successful networking and developed useful insights into the Latin American market. We look forward to meeting you all again in the near future.


Zenoaq Names New Company President to succeed Mr. Keiichi Takano

May 22, 2018

Nipppon Zenyaku Kogyo co., Ltd., also known as Zenoaq, is pleased to announce that at its recent annual shareholders' meeting held on the 22nd of May in Koriyama City, Japan, it was unanimously decided that Mr. Toshikazu Fukui becomes the new Company President, effective May 22, 2018. Toshikazu Fukui succeeds Keiichi Takano, who was Company President from 2009. Mr. Takano will continue as a Board Member in his new capacity as Corporate Consultant.


Toshikazu Fukui, Nippon Zenyaku Kogyo Co., Ltd. Company President

Brief personal history
1998~2008: Joined Zenoaq General Affairs Department
2008~2011: Division Director of International Business based at the Zenoaq Beijing
        Representative Office, China
2011~2016: Company President of Nippon Biologicals Inc. [Zenoaq affiliate]
2013~2016: Executive Director of International Business at Zenoaq
2016~   : Company President of Vetoquinol Zenoaq KK.
2016~2018: Executive Vice President
2018~   : Company President